Hyperfine Inc (NASDAQ:HYPR), the developer of the portable Swoop® brain MRI system, reported financial results for the fourth quarter and full year of 2025 that showcased accelerating revenue growth alongside a narrowing net loss. The company's performance relative to analyst expectations and its forward-looking guidance appear to be driving a positive market reaction in after-hours trading.
Earnings and Revenue Versus Estimates
For the critical fourth quarter, Hyperfine delivered a top-line beat while its bottom-line loss was slightly better than anticipated.
- Q4 2025 Revenue: Reported $5.29 million, surpassing the analyst consensus estimate of approximately $5.26 million. This represents a significant 128% increase from the $2.32 million reported in Q4 2024.
- Q4 2025 EPS: Reported a net loss of $0.06 per share. This figure is narrower than the estimated loss of $0.08 per share (Non-GAAP) provided in the context. It also marks a substantial improvement from the $0.14 per share loss in the prior-year period.
The full-year picture shows more modest growth but improving margins. Full-year 2025 revenue reached $13.56 million, a 5.2% increase over 2024. The annual net loss per share improved to $0.43 from $0.56 in 2024.
Market Reaction and Performance
The initial market response to the earnings report has been strongly positive. Following the release, Hyperfine's stock was indicated up approximately 6.2% in after-market trading. This immediate reaction suggests investors are encouraged by the revenue beat, improved profitability metrics, and the company's outlook.
This positive momentum builds upon recent gains. Over the past month, the stock has advanced roughly 18%, indicating growing investor confidence leading into the earnings announcement.
Business Highlights and 2026 Outlook
Beyond the financial figures, the press release highlighted several operational milestones that underpin the company's growth narrative. Key achievements include the FDA clearance of an advanced AI software update for stroke detection, regulatory approval in India, a $3.7 million grant from the Gates Foundation, and significant capital raises that extend the company's cash runway into 2028.
Crucially, management provided formal financial guidance for 2026, which aligns favorably with existing analyst projections and likely contributed to the positive market sentiment.
- Hyperfine's 2026 Revenue Guidance: $20 to $22 million, representing approximately 55% growth at the midpoint.
- Analyst Sales Estimate for 2026: $18.36 million. The company's own forecast is notably more optimistic than the current analyst consensus, pointing to management's confidence in the commercial rollout of its second-generation Swoop scanner and expansion into neurology office settings.
Furthermore, management expects its cash burn to decline by about 10% in 2026 compared to 2025, signaling a focus on improving operational efficiency as revenue scales.
Financial Health and Path Forward
The earnings report paints a picture of a company in transition. While Hyperfine is not yet profitable, the trends are moving in the right direction: revenue growth is accelerating, gross margins are expanding (51% in Q4 2025 vs. 36% in Q4 2024), and operating expenses are being managed effectively. The strengthened balance sheet, bolstered by recent equity and debt financing, provides the capital necessary to execute its growth strategy without immediate funding concerns.
For a detailed look at Hyperfine's historical earnings performance and to view future analyst projections and estimates, you can visit its earnings page and analyst forecasts page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, nor does it recommend buying or selling any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.